BioSpace

Milestone Sanfilippo nod helps Ultragenyx regroup after tough Angelman defeat

The recent FDA approval of Fayuvi for a rare, childhood neurodegenerative disease was “particularly special” for Ultragenyx CEO Emil Kakkis. It could also, along with an August nod for another gene therapy, help offset recent challenges brought on by two asset failures.

By BioSpace

1 min read
Milestone Sanfilippo nod helps Ultragenyx regroup after tough Angelman defeat
Milestone Sanfilippo nod helps Ultragenyx regroup after tough Angelman defeat

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights